Parvovirus B19V DNA contamination in Chinese plasma and plasma derivatives

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Zhang, Wei ^a   Ke, Ling ^a   Changqing, Li ^a   Zhang, Yan ^b   Li, Wuping ^a,c  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b Cheng Du Rongsheng Pharmaceuticals Co LTD   (China)

^c INSTITUTE OF PATHOGEN BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRINOGEN; GENOMIC DNA; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTHROMBIN COMPLEX; SERUM ALBUMIN; VIRUS ANTIBODY; VIRUS DNA;

ARTICLE; BLOOD DONOR; BLOOD SAFETY; CHINESE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN PARVOVIRUS B19; PLASMA; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; VIRAL CONTAMINATION; VIRUS GENOME; VIRUS LOAD;

CHINA; DNA, VIRAL; HUMANS; PARVOVIRUS B19, HUMAN; POLYMERASE CHAIN REACTION;

EID: 84866155325     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-194     Document Type: Article

References (40)

1. Clewley JP. Biochemical characterization of a human parvovirus. J Gen Virol 1984, 65(Pt 1):241-245.
2. Cotmore SF, Tattersall P. Characterization and molecular cloning of a human parvovirus genome. Science 1984, 226(4679):1161-1165. 10.1126/science.6095448, 6095448.
3. Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CL, Cohen BJ, Mortimer PP, Pereira MS. Human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet 1983, 1:1378.
4. White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA. Human parvovirus arthropathy. Lancet 1985, 1(8426):419-421.
5. Parsyan A, Candotti D. Human erythrovirus B19 and blood transfusion - an update. Transfus Med 2007, 17:263-278. 10.1111/j.1365-3148.2007.00765.x, 17680952.
6. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988, 25:151-153. 10.1099/00222615-25-2-151, 3339634.
7. Eis-Hubinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis KE. The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zbl Bakt 1996, 284:232-240.
8. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999, 13:194-204. 10.1016/S0887-7963(99)80033-9, 10425692.
9. Aubin JT, Defer C, Vidaud M, Maniez Montreuil M, Flan B. Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang 2000, 78(1):7-12. 10.1046/j.1423-0410.2000.7810007.x, 10938920.
10. Saldanha J. Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J Clin Virol 2001, 20:7-13. 10.1016/S1386-6532(00)00149-9, 11163577.
11. Schmidt I, Blumel J, Seitz H, Willkommen H, Lower J. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang 2001, 81:228-235. 10.1046/j.1423-0410.2001.00120.x, 11903998.
12. Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992, 39(3):228-230. 10.1002/ajh.2830390315, 1312304.
13. Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M. Eliminating parvovirus B19 from blood products. Lancet 1994, 343(8900):798.
14. Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, Tchernia G. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Nouv Rev Fr Hematol 1994, 36(6):449-453.
15. Rollag H, Patou G, Pattison JR, Degre M, Evensen SA, Froland SS, Glomstein A. Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis 1991, 23:675-679. 10.3109/00365549109024292, 1815327.
16. Hourfar MK, Mayr-Wohlfart U, Themann A, Sireis W, Seifried E, Schrezenmeier H, Schmidt M. Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion 2011 Jan, 51(1):129-136.
17. Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion 2011 Sep, 51(9):1887-1895.
18. Kleinman SH, Glynn SA, Lee TH, Tobler LH, Schlumpf KS, Todd DS, Qiao H, Yu MY, Busch MP. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009, 114:3677-3683. 10.1182/blood-2009-06-225706, 2766683, 19687508.
19. Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001, 41:130-135. 10.1046/j.1537-2995.2001.41010130.x, 11161258.
20. Tabor E, Yu MY, Hewlett I, Epstein JS. Summary of a workshop on the implementation of NAT to screen donors of blood and plasma for viruses. Transfusion 2000, 40:1273-1275. 10.1046/j.1537-2995.2000.40101273.x, 11061868.
21. Geng Y, Wu CG, Bhattacharyya SP, Tan D, Guo ZP, Yu MY. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007, 47:883-889. 10.1111/j.1537-2995.2007.01205.x, 17465954.
22. Siegl G, Cassinotti P. Presence and significance of parvovirus B19 in blood and blood products. Biologicals 1998, 26:89-94. 10.1006/biol.1998.0138, 9811511.
23. Weimer T, Streichert S, Watson C, Gröner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001, 41(12):1500-1504. 10.1046/j.1537-2995.2001.41121500.x, 11778063.
24. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997, 72(1):1-10. 10.1046/j.1423-0410.1997.00001.x, 9031493.
25. He M, Zhu J, Yin H, Ke L, Gao L, Pan Z, Yang X, Li W. Human immunodeficiency virus/human parvovirus B19 co-infection in blood donors and AIDS patients in Sichuan, China. Blood Transfus 2012 Jun, 27:1-13.
26. Ke L, He M, Li C, Liu Y, Gao L, Yao F, Li J, Bi X, Lv Y, Wang J, et al. The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Transfusion 2011 Sep, 51(9):1909-1918.
27. The guideline of the technological methods and validation of viral removal/inactivation of blood products 2002, Ministry of Health of the People's Republic of China, No. 2002-160.
28. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996, 93:714-719. 10.1046/j.1365-2141.1996.d01-1679.x, 8652400.
29. Eis-Hubinger AM, Sasowski U, Brackmann HH. Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost 1999, 81:476-477.
30. Zakrzewska K, Azzi A, Patou G, Morfini M, Rafanelli D, Pattison JR. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. Br J Haematol 1992, 81:407-412. 10.1111/j.1365-2141.1992.tb08248.x, 1390215.
31. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993, 31:323-328. 262759, 8432819.
32. Lefrere JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 1994, 343:211-212. 10.1016/S0140-6736(94)90993-8, 7904670.
33. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002, 15:485-505. 10.1128/CMR.15.3.485-505.2002, 118081, 12097253.
34. Bizjak G, Blondin D, Hammer R, Kozlowski P, Siegmann HJ, Stressig R. Acute infection with parvovirus B19 in early pregnancy. Ultrasound Obstet Gynecol 2009, 34:234-235.
35. Buyukkose M, Kozanoglu E, Basaran S, Bayramoglu O, Yarkin F. Seroprevalence of parvovirus B19 in fibromyalgia syndrome. Clin Rheumatol 2009, 28:305-309. 10.1007/s10067-008-1044-4, 19057847.
36. van Elsacker-Niele AM, Kroes AC. Human parvovirus B19: relevance in internal medicine. Neth J Med 1999, 54:221-230. 10.1016/S0300-2977(99)00011-X, 10399450.
37. Willkommen H, Schmidt I, Lower J. Safety issues for plasma derivatives and benefit from NAT testing. Biologicals 1999, 27:325-331. 10.1006/biol.1999.0227, 10686059.
38. Morfini M, Longo G, Rossi Ferrini P, Azzi A, Zakrewska C, Ciappi S, Kolumban P. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus. Am J Hematol 1992, 39:149-150. 10.1002/ajh.2830390217, 1550108.
39. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996, 93:457-459. 10.1046/j.1365-2141.1996.5161062.x, 8639448.
40. Yee TT, Lee CA, Pasi KJ. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet 1995, 345:794-795.